Abstract
We assessed a possible role for high-risk human papillomavirus (HPV) testing in the policy after treatment for cervical intraepithelial neoplasia (CIN) 2 or 3 (moderate to severe dysplasia). According to the Dutch guidelines follow-up after treatment consists of cervical cytology at 6, 12 and 24 months. Colposcopy is only performed in case of abnormal cervical cytology. In this observational study 184 women treated for CIN 2 or 3 were prospectively monitored by cervical cytology and high-risk HPV testing 3, 6, 9, 12 and 24 months after treatment. Post-treatment CIN 2/3 was present in 29 women (15.8%). A positive high-risk HPV test 6 months after treatment was more predictive for post-treatment CIN 2/3 than abnormal cervical cytology (sensitivity 90% and 62% respectively, with similar specificity). At 6 months the negative predictive value of a high-risk HPV negative, normal smear, was 99%. Largely overlapping, partly different groups of women with post-treatment CIN 2/3 were identified by HPV testing and cervical cytology. Based on these results we advocate to include high-risk HPV testing in monitoring women initially treated for CIN 2/3. In case of a high-risk HPV positive test or abnormal cervical cytology, colposcopy is indicated. All women should be tested at 6 and 24 months after treatment and only referred to the population-based cervical cancer screening programme when the tests are negative on both visits. © 2001 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Alvarez RD, Helm CW, Edwards RP, Naumann RW, Patridge EE, Shingleton HM, McGee JA, Hall J, Higgins RV and Malone JM (1994) Prospective randomized trial of LLETZ versus laser ablation in patients with cervical intraepithelial neoplasia. Gynecol Oncol 52: 175–179
Benedet JL, Miller DM and Nickerson KG (1992) Results of conservative management of cervical intraepithelial neoplasia. Obstet Gynecol 79: 105–110
Bigrigg A, Haffenden DK, Sheehan AL, Codling BW and Read MD (1994) Efficacy and safety of large-loop excision of the transformation zone. Lancet 343: 32–34
Bistoletti P, Zellbi A, Moreno-Lopez J and Hjerpe A (1988) Genital papillomavirus infection after treatment for cervical intraepithelial neoplasia (CIN) III. Cancer 62: 2056–2059
Bollen LJM, Tjong-A-Hung SP, Mol BW, van der Velden J, ten Kate FJW, ter Schegget J and Bleker OP (1999) Prediction of recurrent cervical dysplasia by human papillomavirus detection among patients with abnormal cytology. Gynecol Oncol 72: 199–201
Chua KL and Hjerpe A (1997) Human papillomavirus analysis as a prognostic marker following conization of the cervix uteri. Gynecol Oncol 66: 108–113
Duncan ID (1997). Guidelines for Clinical Practice and Programme Management, pp. 13–14, National Coordinating Network, NHS Cervical Screening Programme: London
Elfgren K, Bistoletti P, Dillner L, Walboomers JMM, Meijer CJLM and Dillner J (1996) Conization for cervical intraepithelial neoplasia is followed by disappearance of human papillomavirus deoxyribonucleic acid and a decline in serum and cervical mucus antibodies against human papillomavirus antigens. Am J Obstet Gynecol 174: 937–942
Gunasekera PC, Phipps JH and Lewis BV (1990) Large loop excision of the transformation zone (LLETZ) compared to carbon dioxide laser in the treatment of CIN: a superior mode of treatment. Br J Obstet Gynaecol 97: 995–998
Hanselaar AGJM (1995) Het bevolkingsonderzoek op baarmoederhalskanker. Een uniform model voor cytopathologisch onderzoek. Med Contact 50: 1590–1592
Heintz APM (1995) Het bevolkingsonderzoek op baarmoederhalskanker. Patiënten met een afwijkende uitstrijk. Vervolg-en natraject. Med Contact 50: 1593
Helmerhorst THJM and Wijnen JA (1998) Richtlijnen bevolkingsonderzoek baarmoederhalskanker. Ned Tijdschr Obstet Gynaecol 111: 264–265
Ho GYF, Bierman R, Beardsley L, Chang CJ and Burk RD (1998) Natural history of cervicovaginal papillomavirus infection in young women. N Engl Med J 338: 423–428
Jacobs MV, van den Brule AJC, Snijders PJF, Meijer CLJM, Helmerhorst THJM and Walboomers JMM (1997) A general primer GP5+/6+ mediated PCR-EIA for rapid detection of high- and low-risk HPV DNA in cervical scrapes. J Clin Microbiol 35: 791–795
Maclean AB (1984) Healing of cervical epithelium changes after laser treatment of cervical intraepithelial neoplasia. Br J Obstet Gynaecol 91: 697–706
Mann CH, Kehoe S, Brown A and Luesley DM (1999) A study of the follow up patterns of women treated for CIN 2 and 3 before and after the introduction of the 1992 guidelines. Br J Obstet Gynaecol 106: 1126–1129
Mitchell MF, Tortolero-Luna G, Cook E, Whittaker L, Rhodes-Morris H and Silva E (1998) A randomized clinical trial of cryotherapy, laser vaporization, and loop electrosurgical excision for treatment of squamous intraepithelial lesions of the cervix. Obstet Gynecol 92: 737–744
Nobbenhuis MAE, Walboomers JMM, Helmerhorst THJM, Rozendaal L, Remmink AJ, Risse EKJ, van der Linden HC, Voorhorst FJ, Kenemans P and Meijer CJLM (1999) Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening. Lancet 354: 20–25
Nuovo GJ and Pedemonte BM (1990) Human papillomavirus types and recurrent cervical warts. JAMA 263: 1223–1226
Remmink AJ, Walboomers JMM, Helmerhorst THJM, Voorhorst FJ, Rozendaal L, Risse EKJ, Meijer CJLM and Kenemans P (1995) The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int J Cancer 61: 306–311
Walboomers JMM, Jacobs MV, van Oostveen JW, van den Brule AJC, Snijders PJF and Meijer CJLM (1995) Detection of genital human papillomavirus infections and possible clinical implications. Human Papillomavirus Infections in Dermatovenerology, Gross G, Von Krogh G (eds.) pp. 341–364, CRC Press: New York
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Nobbenhuis, M., Meijer, C., van den Brule, A. et al. Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia. Br J Cancer 84, 796–801 (2001). https://doi.org/10.1054/bjoc.2000.1689
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1689
Keywords
This article is cited by
-
p16/Ki-67 dual stain, PAP cytology and HR-HPV test results prior to and 6 months after a LLETZ procedure: a prospective observational cohort study
Archives of Gynecology and Obstetrics (2022)
-
CIN2+ detection of the HPV DNA Array genotyping assay in comparison with the Cobas 4800 HPV test and cytology
Virology Journal (2019)
-
High risk HPV testing following treatment for cervical intraepithelial neoplasia
Irish Journal of Medical Science (1971 -) (2016)
-
Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada
BMC Public Health (2012)
-
The role of HPV DNA testing in the follow-up of cervical intraepithelial neoplasia after loop electrosurgical excision procedure
Archives of Gynecology and Obstetrics (2011)